PRIGNANO, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.286
EU - Europa 8.271
AS - Asia 6.726
SA - Sud America 1.320
AF - Africa 229
OC - Oceania 79
Continente sconosciuto - Info sul continente non disponibili 1
Totale 27.912
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.009
RU - Federazione Russa 2.621
IT - Italia 2.307
SG - Singapore 1.816
CN - Cina 1.607
PL - Polonia 1.122
BR - Brasile 1.048
HK - Hong Kong 920
VN - Vietnam 802
IE - Irlanda 610
KR - Corea 528
SE - Svezia 448
BD - Bangladesh 331
DE - Germania 298
FR - Francia 248
FI - Finlandia 210
IN - India 163
CA - Canada 156
JP - Giappone 145
GB - Regno Unito 117
AR - Argentina 99
CI - Costa d'Avorio 98
JO - Giordania 83
ID - Indonesia 80
AU - Australia 76
UA - Ucraina 74
MX - Messico 49
CH - Svizzera 48
TR - Turchia 48
EC - Ecuador 46
IQ - Iraq 45
NL - Olanda 43
CO - Colombia 36
ZA - Sudafrica 29
PY - Paraguay 25
ES - Italia 22
UZ - Uzbekistan 22
PK - Pakistan 21
VE - Venezuela 20
EG - Egitto 18
AE - Emirati Arabi Uniti 17
CL - Cile 17
JM - Giamaica 17
KE - Kenya 17
MA - Marocco 16
SA - Arabia Saudita 16
NG - Nigeria 15
BE - Belgio 14
PE - Perù 12
CZ - Repubblica Ceca 11
AT - Austria 9
DO - Repubblica Dominicana 9
HN - Honduras 9
MY - Malesia 9
AZ - Azerbaigian 8
BO - Bolivia 8
GT - Guatemala 8
NP - Nepal 8
PH - Filippine 8
UY - Uruguay 8
AL - Albania 7
DZ - Algeria 7
HR - Croazia 7
LT - Lituania 7
OM - Oman 7
RO - Romania 7
BJ - Benin 6
DK - Danimarca 6
IR - Iran 6
PR - Porto Rico 6
TN - Tunisia 6
IL - Israele 5
SV - El Salvador 5
TT - Trinidad e Tobago 5
BY - Bielorussia 4
GR - Grecia 4
NO - Norvegia 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TW - Taiwan 4
BA - Bosnia-Erzegovina 3
CR - Costa Rica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
TH - Thailandia 3
BB - Barbados 2
BG - Bulgaria 2
BH - Bahrain 2
ET - Etiopia 2
HU - Ungheria 2
KH - Cambogia 2
LK - Sri Lanka 2
MN - Mongolia 2
RE - Reunion 2
SM - San Marino 2
Totale 27.886
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.443
Ashburn 1.347
Singapore 1.276
Warsaw 1.113
Hong Kong 765
Dublin 604
Fairfield 585
Chandler 553
Seoul 525
Milan 418
San Jose 371
Buffalo 327
Hefei 300
Beijing 298
Ho Chi Minh City 283
Woodbridge 277
Lawrence 274
Altamura 272
Los Angeles 260
The Dalles 258
Rome 247
Seattle 226
Houston 224
Wilmington 223
Cambridge 213
Council Bluffs 187
Munich 185
Moscow 179
Princeton 174
Hanoi 167
Lauterbourg 167
Medford 148
New York 142
Tokyo 142
Ann Arbor 111
Florence 104
Abidjan 98
San Diego 93
Jacksonville 86
Helsinki 85
São Paulo 85
Shanghai 69
Naples 68
Boston 63
Melbourne 62
Dallas 59
Kent 58
Chicago 57
Mumbai 54
Toronto 48
Boardman 46
Figino 44
Norwalk 44
Paris 40
Haiphong 39
Turin 39
Bologna 38
Bern 35
Da Nang 35
Jakarta 35
Rio de Janeiro 34
Turku 33
Miano 31
Palermo 31
Bengaluru 28
Izmir 28
Chennai 25
Genoa 25
London 24
Orem 24
Montreal 23
Brooklyn 22
Bari 21
Biên Hòa 21
Frankfurt am Main 21
Guangzhou 20
Hillsboro 20
Hải Dương 20
Phoenix 20
Redondo Beach 20
Tianjin 20
Atlanta 19
Cagliari 19
Catania 19
Baghdad 18
Belo Horizonte 18
Curitiba 18
Shenzhen 18
Tashkent 18
Verona 18
Andover 17
Brasília 17
Guayaquil 17
Brescia 16
Campinas 16
Charlotte 16
Salt Lake City 16
San Francisco 16
Modena 15
Lappeenranta 14
Totale 17.604
Salva come PNG Salva come JPEG
Nome #
Lesioni cutanee «specifiche» in corso di leucemia linfatica cronica. 629
Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy 359
CD30+ cutaneous T-cell lymphoma associated with sarcoidosis 343
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 337
SIRT1 regulates MAPK pathways in vitiligo skin: insight into the molecular pathways of cell survival 322
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 321
The involvement of Smac/DIABLO, p53, NF-kB and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin 307
Ultrastructural and functional alterations of mitochondria in perilesional vitiligo skin. 287
Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment 286
New and experimental treatments of vitiligo and other hypomelanoses. 235
Prurigo nodularis and lichen simplex chronicus. 232
Efalizumab in the treatment of psoriasis: when comorbidity is an issue. 228
Comparison of body weight and clinical-parameter changes following the treatment of plaque psoriasis with biological therapies. 226
A rational approach to the treatment of vitiligo and other hypomelanoses. 216
The importance of genetical link in immuno-mediated dermatoses: psoriasis and vitiligo. 206
Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa 206
Fibroblasts to keratinocytes redox signaling: The possible role of ROS in psoriatic plaque formation 204
Circulating dendritic cell subsets in psoriatic patients before and after biologic therapy 200
Psoriasis and body mass index. 194
Retrospective analysis of systemic treatments for psoriasis patients attending a Psocare center in Florence. Relevance of biological drugs use and comorbidities. 192
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 182
Vogt-Koyanagi-Harada disease and vitiligo: where does the illness begin? 181
Secukinumab reduces plasma oxidative stress in psoriasis: A case-based experience 179
Cutaneous sarcoidosis during rituximab treatment for microscopic polyangiitis: An uncommon adverse effect? 178
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 178
Therapeutical approaches in melasma. 177
Protease-activated receptor-2 downregulation is associated to vitiligo lesions 174
Switch from etanercept to efalizumab in a psoriatic patient with HCV infection: a case report. 171
A mesenchyme-derived substrate is necessary for keratinocytes differentiation but not proliferation (Abs. 148). 170
In-vivo imaging of psoriatic lesions with polarization multispectral dermoscopy and multiphoton microscopy 170
Efalizumab-induced severe thrombocytopenia can be resolved. 165
Quantity, distribution and immunophenotypical modification of dendritic cells upon biological treatments in psoriasis. 163
Unusual presentation of tuberculosis in an infliximab-treated patient--which is the correct TB screening before starting a biologic? 163
Polygenic Score: A Tool for Evaluating the Genetic Background of Sporadic Hidradenitis Suppurativa 162
Tuscan consensus on the diagnosis, treatment and follow-up of moderate-to-severe psoriasis 161
Mast cells do not play a role in vitiligo 159
Lichen planus triggered by CT-P13 and recurrence during secukinumab treatment 159
Epidemiology of Psoriasis and Psoriatic Arthritis in Italy—a Systematic Review 155
Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus 155
Treatment of Psoriasis with Efalizumab in Patients with Hepatitis C Viral Infection: Report of Five Cases. 154
Cutaneous hyperpigmentation induced by apremilast 154
Sequential effects of photodynamic treatment of basal cell carcinoma 153
The role of the dermatologist in Raynaud's Phenomenon: a clinical challenge 152
NADPH Oxidase 4 as a Source of Oxidative Stress in Fibroblasts From Patients Affected by Psoriasis 150
Mental health consequences of the covid-19 pandemic long-term exposure in italian dermatologists 150
What's new in malignant melanoma - treatment 150
Evidence for oxidative stress in the plasma of psoriatic patients: Source of ROS and results of treatments with biologics 149
High frequency ultrasound can detect improvement of lesions in juvenile localized scleroderma 149
Reduction in psoriasis related pruritus during biologic therapy* 149
Source of oxidative stress in fibroblasts from patients affected by psoriasis 148
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice 148
A pediatric case of sclerodermatous graft-versus-host disease responsive to ultraviolet A1 phototherapy 148
Induction of CD83+ CD14+ non-dendritic antigen-presenting cells by exposure of monocytes to IFN-alpha1 147
Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study 145
The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? 143
Insights into the pathogenesis of HS and therapeutical approaches 143
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 143
Interleukin 22 early affects keratinocyte differentiation, but not proliferation, in a three-dimensional model of normal human skin. 142
Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars 142
Intellectual Disability and Hidradenitis Suppurativa 141
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis 140
Possible reconsideration of the Nail Psoriasis Severity Index (NAPSI) score 139
Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry 139
Scabies: should we always perform dermatoscopy? 138
Hidradenitis suppurativa and associated diseases 138
Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis 138
Alpha-smooth muscle actin axpression by fibroblasts is not a marker of hypertrophic scars in vitro (Abs. 774). 135
Effects of GM-CSF and TNF-alpha on the Langerhans cells of human epidermal sheets (Abs. 827). 135
Vitiligo masks malignant acanthosis nigricans in a woman with ovarian cancer 135
Epidermal barrier reaction to an in vitro psoriatic microenvironment 135
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study 135
Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions 134
Safety and efficacy of HCV eradication during etanercept treatment for severe psoriasis 133
Comment on “Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?” 133
Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. 132
Hidradenitis suppurativa and adalimumab in the COVID-19 era 132
Involvement of PAR-2 in vitiligo 131
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 130
First case of secukinumab successful therapy in a very elderly psoriatic patient 130
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders 130
Clinical experience with the etanercept biosimilar SB4 in psoriatic patients 130
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: a combined approach by QuantiFERON-TB Gold and tuberculin skin tests. 129
Tumor necrosis factor-alpha and interleukin-17 differently affects Langerhans cell distribution and activation in an innovative three-dimensional model of normal human skin 128
Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis 128
Effect of a psoriatic microenvironment in a three-dimensional model of normal human skin 127
Clinical characteristics of psoriasis in inflammatory bowel disease patients 127
Morphologic and antigenic features of dendritic cells in immune-mediated dermatoses: A hypothesis of differentiation 126
Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: Correlation with clinical, dermatological, serological and genetic indices 126
Atypical mycobacteria 126
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study 125
Smooth-muscle actin, desmin and prolyl 4-hydroxylase in fibroblasts grown from hypertrophic scars and keloids (Abs. 99). 124
Photodynamic therapy and apoptosis in cutaneous basal cell carcinoma (Abs 002). 123
Skin manifestations in psoriatic and hs patients in treatment with biologicals during the covid‐19 pandemic 122
Factors influencing number and differentiation of Langerhans cells within epidermis (Abs P9). 120
Intermediate filament proteins of keratinocytes under different culture conditions (Abs. 244). 120
Clinical experience with infliximab biosimilar in psoriasis 120
Elderly psoriatic patients under biological therapies: an Italian experience 119
PSOCUBE, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm 117
Tuberculosis reactivation risk in dermatology 117
Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study 117
Totale 16.995
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.951
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.951
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.249 33 60 51 29 6 102 184 87 64 41 326 266
2022/20232.763 292 681 127 180 157 493 325 99 242 16 71 80
2023/2024924 38 81 186 43 36 65 49 215 18 76 75 42
2024/20257.588 323 897 536 982 2.135 829 210 378 490 181 278 349
2025/202611.906 946 1.325 1.030 1.223 1.106 290 1.023 569 1.080 881 628 1.805
2026/2027340 340 0 0 0 0 0 0 0 0 0 0 0
Totale 28.166